Table 1.
Application of iRGD conjugation with therapeutic agents to improve the drug efficacy.
| Vehicles | APIa | Cancer Type | Ref |
|---|---|---|---|
| Liposomes | PEDFb DNA | Colorectal cancer (CT26) | [97] |
| none | Breast cancer (4T1) | [98] | |
| Doxorubicin | Breast cancer (4T1), melanoma (B16-F10) | [107,113,114,115] | |
| Lycobetaine Octreotide | Glioma (C6) | [116] | |
| Polymeric NPsc | Doxorubicin | Breast cancer (4T1), liver cancer (VX2) | [112,117,118,119] |
| Paclitaxel | Gastric cancer (MKN-45P), colon cancer (CT26), hepatoma (H22), breast cancer (4T1) | [110,120,121] | |
| Carmustine O6-enzylguanine |
Glioma (F98, C6, U87) | [122] | |
| Tamoxifen | Breast cancer (MCF-7, T47D) | [123] | |
| Isoliquiritigenin | Breast cancer (4T1) | [111] | |
| Silica NPsc | Doxorubicin | Colorectal cancer (HT-29) | [124] |
| Micelles | Paclitaxel | Prostate cancer (PC-3, PPC1), pancreatic cancer (MIA PaCa-2), breast cancer (BT474) | [52] |
| Platinum complex | Glioblastoma (U87) | [103] | |
| Camptothecin | Glioblastoma (U87) | [104] | |
| Docetaxel | HeLa | [108] | |
| Hydrogels | Doxorubicin | Melanoma (B16) | [125] |
| Gambogic acid | Gastric cancer (MKN-45) | [126] | |
| Solid lipid NPsc | siRNA | Glioblastoma (GL261) | [109] |
| Protein NCsd | Paclitaxel | Hepatoma (H22) | [127] |
APIa, Active pharmaceutical ingredient; PEDFb, Pigment epithelium-derived factor; NPsc, Nanoparticles; NCsd, Nanocapsules.